MS Infusion Timing: Why Longer Gaps May Need a Check
By MS Buddy ·
Summarized from Multiple sclerosis (Houndmills, Basingstoke, England), Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Research by Liza Gelissen, Theo Rispens and 6 colleagues at Amsterdam University Medical Centers, Uppsala University and 1 other institution in the Netherlands and Sweden.
Key Takeaway
In one person with MS, changing natalizumab infusions from every four weeks to every six weeks was followed by low drug levels and antibodies that may make the treatment less effective.
What They Found
The person had taken natalizumab for years before switching to a longer gap between infusions. After the switch, the amount of medicine left in their blood just before the next infusion was unexpectedly low. Their body also made increasing amounts of antibodies, which are proteins that can block a medicine or help clear it away. A computer model suggested that falling drug levels may have helped trigger these antibodies. The researchers warned that this cycle could leave less medicine available to control MS and raise the risk of new disease activity.
Who Should Care and Why
This finding matters most to people taking natalizumab on a longer infusion schedule and to the caregivers who help track their care. A longer gap may be convenient, but this case shows why it is worth discussing the plan with your MS care team. Think of drug levels like fuel in a tank: the researchers found that the level was unusually low before the next scheduled refill. Ask your care team whether they need to check how well the treatment is working, especially if you notice new or worsening symptoms. Do not change your infusion schedule on your own; your care team can weigh the possible benefits and risks for you.
Important Considerations
This report describes just one person, so it cannot show how often this happens to others with MS. The computer model suggested a possible reason for the antibody increase, but it could not prove that longer gaps caused it. The report does not show that everyone on a six-week schedule needs a change, so decisions should be made with your MS care team.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Multiple sclerosis (Houndmills, Basingstoke, England) by et al.. Reproduced from the PubMed record.
We present a natalizumab-treated patient with multiple sclerosis (MS) who developed neutralizing anti-drug antibodies (ADAs) after years of treatment following introduction of extended interval dosing (EID). To gain insight into how this sudden ADA development occurred. A pharmacokinetic model was used to evaluate the relation between natalizumab concentration and ADA production. EID from 4 to 6 weeks resulted in unexpectedly low natalizumab trough concentrations accompanied by increasing ADAs. Modeling suggested ADA production was stimulated by declining natalizumab concentrations. EID may result in increased ADA production, causing ADA-mediated clearance of natalizumab and risking new MS activity.
Trials you could look into
This study looked at a treatment with MS trials currently recruiting or under way.
Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.
Explore more research
Related MS research

11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read More
11/14/2026
An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu
Read More
11/14/2026
In a study of people with MS, those with greater disability reported more voice problems and vocal f
Read More
11/15/2026
In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read More
11/12/2026
In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
